PUBLIC SUBMISSION STATEMENT – 15 February 2025
SUBJECT: Gene Technology Bill – OPPOSITION
OVERALL:
New Zealand should pause and take a “wait and see” approach on this Bill until more factual science, objective
international results, and extensive public input are gathered. Given the potential risks, this decision should go to a
Public Referendum, allowing New Zealanders to make an informed choice rather than having it imposed. NZers
deserve bodily autonomy and full informed consent.
Why is New Zealand, under Attorney-General Judith Collins, pushing this Bill when 26 countries have partially
banned GMOs? Are we once again being used as a global testing ground? (Note: Collins also holds key positions in
defence, GCSB, NZDSIS, space, and digital governance—raising questions about her priorities and allegiances.)
A strong precautionary approach is required – we want truth and transparency. Once the genie is out of the bottle,
NZ won’t recover on a multitude of levels.
POINTS OF CONCERN:
1) Labelling Requirements Critical –
The Bill removes the labelling requirement for gene-altered foods, allowing regulators to alter the national diet
without transparency. This violates the New Zealand Bill of Rights, specifically provision 10, as it exposes people to
unconsented scientific experimentation on health.
2) Economic Necessity –
- High Failure Rate: Only 18% of biotech startups reach the market, and few generate significant revenue,
with bankruptcies peaking in 2023 (US National Center for Biotechnology Information). - Unrealistic Promises: The biotech industry relies on aggressive PR, often exaggerating potential success to
attract investment and government grants. - Government-Mandated Use: The industry’s goal is mandated adoption, as seen during the pandemic,
leading to excessive corporate profits at public expense. Dr. Guy Hatchard – Biotechnology Threatens
Humans… (Feb 2025) - Economic Risks: Over-reliance on biotech can strain public finances, creating long-term debt and economic
instability. - Questionable Growth Strategy: Deregulation is positioned as essential for economic growth, but the
industry’s track record suggests limited economic benefits and high financial risks.